YKYujin Kim

Yujin Kim

*This is an algorithmically generated author record based on publicly available information.

Yujin Kim has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Novel Variant of FDXR as a Molecular Etiology of Postlingual Post-synaptic Auditory Neuropathy Spectrum Disorder via Mitochondrial Dysfunction: Reiteration of the Correlation between Genotype and Cochlear Implantation Outcomes

    by Bong Jik Kim, Yujin Kim, Ju Ang Kim, Jin Hee Han, Min Young Kim, Hee Kyung Yang, Chae-Seo Rhee, Young Cheol Kang, Chun-Hyung Kim, Byung Yoon Choi

    Objectives. FDXR encodes mitochondrial ferredoxin reductase, which is associated with auditory neuropathy spectrum disorder (ANSD) and optic atrophy. To date, only two studies have described FDXR-related hearing loss. The auditory rehabilitation outcomes of this disease entity have not been investigated, and the pathophysiological mechanisms remain incompletely understood. Here we report a hearing-impaired individual with co-segregation of the FDXR variant and post-synaptic type ANSD, who underwent cochlear implantation (CI) with favorable outcomes. We suggest a possible pathophysiological mechanism of adult-onset ANSD involving mitochondrial dysfunction.Methods. A 35-year-old woman was ascertained to have ANSD. Exome sequencing identified the genetic cause of hearing loss, and a functional study measuring mitochondrial activity was performed to provide molecular evidence of pathophysiology. Expression of FDXR in the mouse cochlea was evaluated by immunohistochemistry. Intraoperatively, electrically evoked compound action potential (ECAP) responses were measured, and the mapping parameters were adjusted accordingly. Audiological outcomes were monitored for over 1 year.Results. In lymphoblastoid cell lines (LCLs) carrying a novel FDXR variant, decreased ATP levels, reduced mitochondrial membrane potential, and increased reactive oxygen species levels were observed compared to control LCLs. These dysfunctions were restored by administering mitochondria isolated from umbilical cord mesenchymal stem cells, confirming the pathogenic potential of this variant via mitochondrial dysfunction. Partial ECAP responses during CI and FDXR expression in the mouse cochlea indicate that FDXR-related ANSD is post-synaptic. As a result of increasing the pulse width during mapping, the patient’s CI outcomes showed significant improvement over 1-year post-CI.Conclusion. A novel FDXR variant associated with mitochondrial dysfunction and post-synaptic ANSD was first identified in a Korean individual. Additionally, 1-year post-CI outcomes were reported for the first time in the literature. Excellent audiologic results were obtained, and our results reiterate the correlation between genotype and CI outcomes in ANSD.


  • Open Access

    Human umbilical cord mesenchymal stem cell-derived mitochondria (PN-101) attenuate LPS-induced inflammatory responses by inhibiting NFκB signaling pathway

    by Shin-Hye Yu, Soomin Kim, Yujin Kim, Seo-Eun Lee, Jong Hyeok Park, Gayoung Cho, Jong-Cheon Ha, Hahnsun Jung, Sang-Min Lim, Kyuboem Han, et al.

    Shin-Hye Yu, Soomin Kim, Yujin Kim, Seo-Eun Lee, Jong Hyeok Park, Gayoung Cho, Jong-Cheon Ha, Hahnsun Jung, Sang-Min Lim, Kyuboem Han, Hong Kyu Lee, Young Cheol Kang & Chun-Hyung Kim. BMB Reports 2022;55:136-41. https://doi.org/10.5483/BMBRep.2022.55.3.083